Antibody Therapies

AHA Special Bulletin
September 17, 2021

ASPR is working with state and territorial leaders to make COVID-19 monoclonal antibody therapies available across all states and territories. The therapies no longer can be ordered directly by hospitals.

https://www.aha.org/system/files/media/file/2021/09/hhs-reinstates-original-distribution-method-for-covid-19-monoclonal-antibody-therapies-9-17-21.pdf

The Department of Health and Human Services’ (HHS) Assistant Secretary for Preparedness and Response (ASPR) Sept. 13 announced a major change in the distribution of COVID-19 monoclonal antibody therapies. This change was prompted by the rapid surge in COVID-19-positive cases across the country, which has greatly increased the demand for monoclonal antibodies as a therapy that has been shown to be effective for many people in preventing severe illness or death if administered early in the course of the disease.

The first monoclonal antibody therapies received Food and Drug Administration emergency use authorization in November 2020, with supplies having since been limited. The initial demand for monoclonal antibodies was much lower than available supply, which is why from February 2021 until Sept. 13, ASPR allowed hospitals and other health care delivery sites to order monoclonal antibodies directly from the supplier (AmerisourceBergen). However, the rapid increase in demand for monoclonal antibodies has significantly constrained supply. To assure an equitable distribution of what has now become a limited resource, the federal government has reverted to the method it used from November 2020 through February 2021 for allocating monoclonal antibodies. It is similar to the method HHS used to allocate COVID-19 vaccines at a time when they, too, were in limited supply.

THE ALLOCATION METHOD

ASPR begins each week by learning from the manufacturers how many doses of monoclonal antibodies will be available. It then uses data collected from hospitals and other providers that is sent to HHS Protect to determine each states’ COVID-19-positive case counts and number of hospitalized patients. These numbers determine the proportion of available monoclonal antibodies each state might receive, but it will be adjusted if a state’s usage rate for monoclonal antibodies suggests it is not using up its prior week’s allocation at a rate similar to that of other states.

Each state governor or their designee will receive notice of the amount to be sent to the state on Tuesday of each week. By Thursday of each week, the state will have to determine how that allocation is to be distributed within the state so that supplier AmerisourceBergen can put it on trucks and deliver it. If the governor or designee indicates that the state does not want the full amount that has been allocated to it, the rest will remain in the warehouse and either be used for urgent situations that require expedited shipment or will become part of the amount of the following week’s therapeutics available for distribution.

WHAT YOU CAN DO

Contact your state hospital association to ensure you know who within your state government will be making the allocation decisions and let that person or persons know of your needs.
Ensure your hospital’s data are being submitted to HHS Protect as required, which will ensure your hospital’s COVID-19 patients are included in the counts that will determine the amount of monoclonal antibodies allocated to your state.

Ensure your clinicians understand and are adhering to the criteria for determining who is likely to benefit from this therapy in order to preserve this limited resource for those who truly need it. These criteria are articulated in the Emergency Use Authorization.